Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million

2026-02-22 14:36:11 ET

On February 17, 2026, Perceptive Advisors disclosed a significant buy of 431,432 shares of Praxis Precision Medicines (NASDAQ:PRAX) , with an estimated transaction value of $80.34 million based on quarterly average pricing, according to its latest SEC filing.

According to a February 17, 2026, SEC filing , Perceptive Advisors LLC increased its stake in Praxis Precision Medicines (NASDAQ:PRAX) by 431,432 shares during the fourth quarter of 2025. The estimated value of this trade was approximately $80.34 million, calculated using the mean unadjusted close price for the period. The quarter-end value of the position increased by $505.38 million, reflecting both the share purchase and subsequent stock price movement.

Praxis Precision Medicines is a Boston-based biotechnology company specializing in the development of novel therapies for disorders characterized by neuronal imbalance. With a focused pipeline addressing major depressive disorder, essential tremor, and rare epilepsies, the company leverages proprietary research and strategic collaborations to advance its candidates through clinical stages. Praxis differentiates itself through its emphasis on precision medicine and targeted central nervous system treatments, aiming to address unmet medical needs in neurology and psychiatry.

Continue reading